Capecitabine monotherapy does not improve survival in elderly patients with early-stage breast cancer

Share :
Published: 11 Dec 2014
Views: 2846
Prof Gunter Von Minckwitz – German Breast Group, Neu-Isenburg, Germany

At a press conference at SABCS 2014, Prof von Minckwitz presents negative data out of the phase III ICE trial.

In elderly breast cancer patients with moderate- to high-risk early-stage disease for whom standard chemotherapy is too toxic, the chemotherapy capecitabine, which causes fewer side effects than the standard chemotherapy agents, did not improve outcomes when tested as monotherapy. 

Watch the interview or read the news story for more.